Penn's new $10M fund backs peptide-discovery startup Peptaris with $250K
What's the deal? PeptarisDealroom has a profile for this one. Try Dealroom →, a biotech startup using AI models to discover peptides for human drug development, has raised $250,000 in pre-seed funding from the University of Pennsylvania's Penn StartUP Fund. The company was co-founded by Presidential Associate Professor César de la Fuente.
The context: Peptaris was one of three faculty-founded companies picked in the fund's inaugural batch, alongside maternal-health startup VasowatchDealroom has a profile for this one. Try Dealroom → and wireless-filter maker OneFiltrDealroom has a profile for this one. Try Dealroom →. Each received the same $250,000 investment.
Why it stands out: The $250,000 sum sits near the bottom of comparable rounds, landing in roughly the 30th percentile — a reflection of the fund's early-stage, non-traditional design rather than commercial traction.
Why now? The $10 million StartUP Fund launched earlier this year to help Penn faculty move their inventions into the commercial space. Companies enter a "simple agreement for equity" with the University, receiving funding without cash repayment obligations.
What's the endgame? De la Fuente said the fund is a way to "translate" the company's research at Penn while expanding the biotech industry in the Philadelphia area.
An impact fund, not a VC: Chief Innovation Officer John Swartley described the initiative as an "impact fund" rather than a traditional venture fund that aims to "reap immediate financial benefits." He said the goal was "to make sure that the startup fund is relevant to the entire Penn community."
The signal: Universities are increasingly acting as first-check investors to keep faculty inventions local. "We're big believers in companies starting here and staying here," Swartley said, adding that the fund "supports good ideas, good opportunities across the entirety of Penn."
Read more: thedp.com
Image credit: Generated with Gemini
